Jacek Zdybski

Ostrowiec Swietokrzyski, SK, Poland

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 13 publications

Long-Term Safety and Efficacy of Dupilumab Treatment in Children Aged 6 Months to 5 Years with Severe Atopic Dermatitis.

Long-Term Safety and Efficacy of Dupilumab Treatment in Children Aged 6 Months to 5 Years with Severe Atopic Dermatitis.

Journal: Paediatric drugs

Published: November 17, 2025

Prolonged ruxolitinib cream treatment for vitiligo among patients with no or limited response in the first 6 months.

Prolonged ruxolitinib cream treatment for vitiligo among patients with no or limited response in the first 6 months.

Journal: Journal of the European Academy of Dermatology and Venereology : JEADV

Published: November 07, 2025

Efficacy and Safety of Nemolizumab at Week 48: Results from the Maintenance Phase of Two Global Phase 3 Pivotal Studies (ARCADIA 1&2) in Patients with Moderate-to-Severe Atopic Dermatitis.

Efficacy and Safety of Nemolizumab at Week 48: Results from the Maintenance Phase of Two Global Phase 3 Pivotal Studies (ARCADIA 1&2) in Patients with Moderate-to-Severe Atopic Dermatitis.

Journal: Acta dermato-venereologica

Published: October 08, 2025

Long-Term Integrated Safety Summary of Ruxolitinib Cream in Phase 3 Clinical Trials of Patients with Vitiligo.

Long-Term Integrated Safety Summary of Ruxolitinib Cream in Phase 3 Clinical Trials of Patients with Vitiligo.

Journal: Dermatology and therapy

Published: August 04, 2025

Open-label treatment extension of ruxolitinib cream in vitiligo: findings from the TRuE-V long-term extension phase 3 study.

Open-label treatment extension of ruxolitinib cream in vitiligo: findings from the TRuE-V long-term extension phase 3 study.

Journal: The British journal of dermatology

Published: June 25, 2025

Open-label treatment extension of ruxolitinib cream in vitiligo: findings from the Topical Ruxolitinib Evaluation in Vitiligo (TRuE-V) long-term extension phase III study.

Open-label treatment extension of ruxolitinib cream in vitiligo: findings from the Topical Ruxolitinib Evaluation in Vitiligo (TRuE-V) long-term extension phase III study.

Journal: The British journal of dermatology

Published: June 25, 2025

Randomized, double-blind treatment withdrawal or continuation with ruxolitinib cream in vitiligo: findings from the TRuE-V long-term extension phase 3 study.

Randomized, double-blind treatment withdrawal or continuation with ruxolitinib cream in vitiligo: findings from the TRuE-V long-term extension phase 3 study.

Journal: The British journal of dermatology

Published: June 13, 2025

Correction to: Efficacy and Safety of Dupilumab Treatment with Concomitant Topical Corticosteroids in Children Aged 6 Months to 5 Years with Severe Atopic Dermatitis.

Correction to: Efficacy and Safety of Dupilumab Treatment with Concomitant Topical Corticosteroids in Children Aged 6 Months to 5 Years with Severe Atopic Dermatitis.

Journal: Advances in therapy

Published: May 02, 2024

Efficacy and Safety of Dupilumab Treatment with Concomitant Topical Corticosteroids in Children Aged 6 Months to 5 Years with Severe Atopic Dermatitis.

Efficacy and Safety of Dupilumab Treatment with Concomitant Topical Corticosteroids in Children Aged 6 Months to 5 Years with Severe Atopic Dermatitis.

Journal: Advances in therapy

Published: September 15, 2023

Comparing abrocitinib and dupilumab in the treatment of atopic dermatitis: a plain language summary.

Comparing abrocitinib and dupilumab in the treatment of atopic dermatitis: a plain language summary.

Journal: Immunotherapy

Published: November 15, 2021

Efficacy and safety of N-acetyl-GED-0507-34-LEVO gel in patients with moderate-to severe facial acne vulgaris: a phase IIb randomized double-blind, vehicle-controlled trial.

Efficacy and safety of N-acetyl-GED-0507-34-LEVO gel in patients with moderate-to severe facial acne vulgaris: a phase IIb randomized double-blind, vehicle-controlled trial.

Journal: The British journal of dermatology

Published: September 28, 2021

Abrocitinib versus Placebo or Dupilumab for Atopic Dermatitis.

Abrocitinib versus Placebo or Dupilumab for Atopic Dermatitis.

Journal: The New England journal of medicine

Published: March 24, 2021

Showing 1-12 of 13

Last Updated: 09/26/2026